---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-109739"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-10-18T23:59:59+00:00"
generated_at: "2026-06-23T02:59:07.585938+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics regains Nasdaq compliance; bid price and equity requirements satisfied; delisting matter closed

## Summary
- On Oct 18, 2022, Nasdaq confirmed Avenue Therapeutics met the $1.00 bid price and $2.5M stockholders' equity requirements for continued listing.
- The delisting matter is closed; the company previously faced potential delisting for non-compliance with both requirements.
- A Nasdaq Hearings Panel granted a stay through Oct 2022 to demonstrate compliance; company successfully met the conditions.
- The company is now in full compliance with all applicable Nasdaq Capital Market listing criteria.

## SEC filing metadata
- accession: 0001104659-22-109739
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-10-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922109739/0001104659-22-109739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922109739/tm2228514d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-109739
- JSON: https://secwatch.observer/filing/0001104659-22-109739.json
- Plain text: https://secwatch.observer/filing/0001104659-22-109739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.